After finishing at $26.58 in the prior trading day, Pfizer Inc. (NYSE: PFE) closed at $26.78, up 0.75%. In other words, the price has increased by $+0.20 from its previous closing price. On the day, 44610643 shares were traded.
Ratios:
Our goal is to gain a better understanding of PFE by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 11.92 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 31.55. For the most recent quarter (mrq), Quick Ratio is recorded 0.69 and its Current Ratio is at 0.91. In the meantime, Its Debt-to-Equity ratio is 0.84 whereas as Long-Term Debt/Eq ratio is at 0.72.
On February 23, 2024, Guggenheim started tracking the stock assigning a Buy rating and target price of $36.
TD Cowen Downgraded its Outperform to Market Perform on January 04, 2024, while the target price for the stock was maintained at $32.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 15 ’23 when Gottlieb Scott bought 3,000 shares for $26.47 per share. The transaction valued at 79,401 led to the insider holds 9,000 shares of the business.
Gottlieb Scott bought 1,000 shares of PFE for $38,580 on May 08 ’23. The Director now owns 6,000 shares after completing the transaction at $38.58 per share. On May 05 ’23, another insider, Gottlieb Scott, who serves as the Director of the company, bought 1,000 shares for $38.42 each. As a result, the insider paid 38,425 and bolstered with 5,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PFE now has a Market Capitalization of 151.64B and an Enterprise Value of 209.80B. As of this moment, Pfizer’s Price-to-Earnings (P/E) ratio for their current fiscal year is 74.51, and their Forward P/E ratio for the next fiscal year is 9.72. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.59 while its Price-to-Book (P/B) ratio in mrq is 1.70. Its current Enterprise Value per Revenue stands at 3.59 whereas that against EBITDA is 21.95.
Stock Price History:
Over the past 52 weeks, PFE has reached a high of $41.99, while it has fallen to a 52-week low of $25.61. The 50-Day Moving Average of the stock is 27.32, while the 200-Day Moving Average is calculated to be 31.17.
Shares Statistics:
The stock has traded on average 42.95M shares per day over the past 3-months and 36.01M shares per day over the last 10 days, according to various share statistics. A total of 5.65B shares are outstanding, with a floating share count of 5.64B. Insiders hold about 0.04% of the company’s shares, while institutions hold 70.15% stake in the company. Shares short for PFE as of Mar 28, 2024 were 65M with a Short Ratio of 1.67, compared to 66.12M on Feb 29, 2024. Therefore, it implies a Short% of Shares Outstanding of 1.15% and a Short% of Float of 1.15%.
Dividends & Splits
In the trailing 12 months, PFE’s forward annual dividend rate was 1.64, compared to 1.65 this year. Against a Trailing Annual Dividend Yield of 6.17%, it implies a Forward Annual Dividend Yield of 6.27%. The stock’s 5-year Average Dividend Yield is 3.97. The current Payout Ratio is 439.41% for PFE, which recently paid a dividend on Mar 01, 2024 with an ex-dividend date of Jan 25, 2024. Stock splits for the company last occurred on Nov 17, 2020 when the company split stock in a 1054:1000 ratio.
Earnings Estimates
Its stock is currently analyzed by 16 different market analysts. On average, analysts expect EPS of $0.54 for the current quarter, with a high estimate of $0.82 and a low estimate of $0.37, while EPS last year was $1.23. The consensus estimate for the next quarter is $0.46, with high estimates of $0.62 and low estimates of $0.35.
Analysts are recommending an EPS of between $2.35 and $2.05 for the fiscal current year, implying an average EPS of $2.2. EPS for the following year is $2.76, with 21 analysts recommending between $3.18 and $2.22.
Revenue Estimates
13 analysts predict $14.2B in revenue for the current quarter. It ranges from a high estimate of $16.46B to a low estimate of $12.75B. As of the current estimate, Pfizer Inc.’s year-ago sales were $16.59B, an estimated decrease of -14.40% from the year-ago figure. For the next quarter, 13 analysts are estimating revenue of $13.24B, an increase of 4.00% over than the figure of -$14.40% in the same quarter last year. There is a high estimate of $14.66B for the next quarter, whereas the lowest estimate is $12.66B.
A total of 22 analysts have provided revenue estimates for PFE’s current fiscal year. The highest revenue estimate was $60.89B, while the lowest revenue estimate was $58.5B, resulting in an average revenue estimate of $60B. In the same quarter a year ago, actual revenue was $58.5B, up 2.60% from the average estimate. Based on 21 analysts’ estimates, the company’s revenue will be $62.92B in the next fiscal year. The high estimate is $65.5B and the low estimate is $60.72B. The average revenue growth estimate for next year is up 4.90% from the average revenue estimate for this year.
